Target intelligence / Profile preview

Campylobacter jejuni cytolethal distending toxin (CDT)

Target
CDT
Molecular classification
Bacterial toxin, Bacterial protein, Genotoxin, Other
01

Overview

Cytolethal distending toxin (CDT) is a major virulence factor secreted by Campylobacter jejuni and consists of three subunits: CdtA, CdtB, and CdtC. CdtB functions as a DNase, inducing DNA double-strand breaks in the nuclei of host cells, which leads to cell cycle arrest and apoptosis, while CdtA and CdtC facilitate toxin entry by binding to cholesterol-rich regions of host cell membranes[2]. CDT plays a central role in Campylobacter pathogenesis, contributing to mucosal damage, invasion, and immune evasion. Other notable Campylobacter proteins involved in virulence include Campylobacter invasion antigens (Cia), which facilitate bacterial entry into host cells, and proteins involved in glycosylation for host adherence[1]. Campylobacter infections are among the most common causes of bacterial gastroenteritis worldwide, with complications such as Guillain–Barré syndrome and reactive arthritis occurring in some cases[1][2][3][4]. There are currently no drugs that directly target Campylobacter toxins; instead, management focuses on controlling infection via antibiotics, though resistance is an increasing concern.

Other names
cytolethal distending toxinCDTCdtACdtBCdtCCampylobacter toxinsCampylobacter proteins
02

Mechanism of action

DNA double-strand break induction by CdtB, leading to cell cycle arrest at the G2/M phase and apoptosis CdtA and CdtC facilitate delivery of CdtB to host cells by binding cholesterol-rich membrane microdomains Cia proteins facilitate host cell invasion, N-linked glycosylation supports adherence and invasion

03

Biological functions

Induction of host cell apoptosisCell cycle arrestDNA damage (genotoxicity)Host cell invasionVirulence
04

Disease associations

InfectionGastroenteritisGuillain–Barré syndrome (indirect)Reactive arthritis (indirect)Other
05

Safety considerations

Potential for severe gastrointestinal diseaseAssociations with Guillain–Barré syndrome and reactive arthritis after infectionGenotoxic risk if toxin repurposed in therapy (proposed in some cancer approaches)Antibiotic resistance of Campylobacter species complicates infection management
06

Interacting drugs

none (no approved drugs directly target CDT; approaches focus on infection control, antibiotics, not direct CDT inhibition)
07

Biomarkers

none specific; Campylobacter antigen or serology may be used for infection diagnosis, not CDT as a therapy biomarker

Beyond the preview

Go deeper on Campylobacter jejuni cytolethal distending toxin (CDT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Campylobacter jejuni cytolethal distending toxin (CDT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call